梅特福明在辐射诱导的 Xerostomia 的预防作用
Sungryeal Kim1, Jeong-Mi Kim1,2, Eun-Jeong Jeon1,3
1Department of Otorhinolaryngology-Head and Neck Surgery, Inha University College of Medicine, 27 Inhang-ro, Jung-gu, Incheon, 22332, Republic of Korea.
Advanced biology
|March 20, 2025
概括
甲福明是一种糖尿病药物,可以预防头癌患者的辐射诱导的唾液腺损伤和功能障碍. 这项研究表明,在放射治疗后,甲福明可以保持唾液腺的结构和功能.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 再生医学是一种再生医学.
背景情况:
- 头部和部癌症的放射治疗会导致唾液腺损伤,导致功能低下和生活质量下降.
- 目前对辐射诱导的唾液功能障碍的预防策略有限.
- 糖尿病药物梅特福明表现出抗炎和组织再生的特性,表明潜在的治疗益处.
研究的目的:
- 调查甲福明在预防辐射诱导的唾液腺损伤和功能障碍方面的疗效.
- 为了评估甲福明对细胞和组织层面的变化对唾液腺辐射后的作用.
- 评估辐射暴露后使用甲福明治疗的唾液腺的功能恢复.
主要方法:
- 在体外:对照射的人类皮上皮细胞进行DNA损伤,炎症 (NF-кB,IL-6) 和增殖的分析.
- 在体内:小鼠模型接受了辐射,随后对唾液腺进行了组织学和功能分析 (唾液流量,滞后时间).
- 在体外和体外模型中,在辐射后给药的甲福明治疗.
主要成果:
- 辐射增加了DNA损伤,炎症和亡,同时减少了唾液细胞的增殖.
- 甲胺治疗显著减少了辐射诱导的DNA损伤和炎症,并增强了细胞增殖.
- 在体内研究表明,甲福明保留了唾液腺膜,并改善了功能参数,与正常对照相比.
结论:
- 甲胺有效地减轻了辐射诱导的结构损伤和唾液腺功能缺陷.
- 甲胺显示出作为一种保护剂的潜力,可以预防与放射治疗相关的唾液腺功能障碍.
- 这项研究支持在接受放射治疗的癌症患者中使用甲福明来预防唾液腺功能障碍.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
170
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
170
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
208
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
208
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
145
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
145
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
230
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
230
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
139
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
139
Peptic Ulcer Disease IV: Management
56
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
56


